EP Patent

EP2218721A1 — Novel salts of sitagliptin

Assigned to Lek Pharmaceuticals dd · Expires 2010-08-18 · 16y expired

What this patent protects

The present invention relates to novel pharmaceutically acceptable salts of sitagliptin, to processes for their preparation and to pharmaceutical compositions containing them.

USPTO Abstract

The present invention relates to novel pharmaceutically acceptable salts of sitagliptin, to processes for their preparation and to pharmaceutical compositions containing them.

Drugs covered by this patent

Steglatro (ERTUGLIFLOZIN) · Merck & Co.

Patent Metadata

Patent number: EP2218721A1
Jurisdiction: EP
Classification: —
Expires: 2010-08-18
Drug substance claim: No
Drug product claim: No
Assignee: Lek Pharmaceuticals dd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.